|
1.
|
|
8 p, 1.5 MB |
Non-pharmacological Effects in Switching Medication : The Nocebo Effect in Switching from Originator to Biosimilar Agent
/
Kristensen, Lars Erik (Lund University. Department of Internal Medicine, Rheumatology) ;
Alten, Rieke (Schlosspark Klinik, University Medicine Berlin. Department of Internal Medicine, Rheumatology) ;
Puig, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Philipp, Sandra (Charité Universitätsmedizin. Department of Dermatology, Venereology and Allergy) ;
Kvien, Tore K. (Diakonhjemmet Hospital. Department of Rheumatology) ;
Mangues, Maria Antonia (Institut d'Investigació Biomèdica Sant Pau) ;
van den Hoogen, Frank (Sint Maartenskliniek and Radboud University Medical Centre. Department of Rheumatology) ;
Pavelka, Karel (Institute of Rheumatology) ;
Vulto, Arnold G. (KU Leuven. Department of Pharmaceutical and Pharmacological Sciences) ;
Universitat Autònoma de Barcelona
The nocebo effect is defined as the incitement or the worsening of symptoms induced by any negative attitude from non-pharmacological therapeutic intervention, sham, or active therapies. When a patient anticipates a negative effect associated with an intervention, medication or change in medication, they may then experience either an increase in this effect or experience it de novo. [...]
2018 -  10.1007/s40259-018-0306-1
Biodrugs, Vol. 32 (september 2018) , p. 397-404
|
|
|
2.
|
|
18 p, 504.6 KB |
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure
/
Armstrong, April (Keck School of Medicine of the University of Southern California. Department of Clinical Research) ;
Paul, Carle (Paul Sabatier University. Dermatology Department, Toulouse University Hospital (CHU)) ;
Puig, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Boehncke, Wolf Henning (University of Geneva. Department of Pathology and Immunology) ;
Freeman, Michael (The Skin Centre, Benowa, QLD Australia) ;
Torii, Hideshi (Tokyo Yamate Medical Center. Division of Dermatology) ;
Papp, Kim (K Papp Clinical Research and Probity Medical Research) ;
Griffiths, Christopher E. M. (NIHR Manchester Biomedical Research Centre. Dermatology Centre, Salford Royal Hospital, University of Manchester) ;
Blauvelt, Andrew (Oregon Medical Research Center) ;
Reich, Kristian (Skinflammation® Center, Hamburg, Germany) ;
Gooderham, Melinda (Centre for Dermatology and Probity Medical Research, Peterborough, ON Canada) ;
Terui, Tadashi (Nihon University School of Medicine. Department of Dermatology) ;
Renda, Lisa (Eli Lilly and Company) ;
Agada, Noah (Eli Lilly and Company) ;
Xu, Wen (Eli Lilly and Company) ;
Gallo, Gaia (Eli Lilly and Company) ;
Lebwohl, Mark G. (Icahn School of Medicine at Mount Sinai. Department of Dermatology) ;
Universitat Autònoma de Barcelona
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. [...]
2019 - 10.1007/s13555-019-00340-3
Dermatology and Therapy, Vol. 10 (november 2019) , p. 133-150
|
|
|
3.
|
|
1 p, 320.3 KB |
Correction to : Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
/
Blauvelt, Andrew (SW Locust St., Suite G, Portland, OR 97223 USA) ;
Papp, Kim A. (Waterloo, Canada) ;
Griffiths, Christopher E. M. (Manchester, UK) ;
Puig, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ;
Dutronc, Yves (Indianapolis, IN USA) ;
Kerr, Lisa Farmer (Indianapolis, IN USA) ;
Ilo, Dapo (Indianapolis, IN USA) ;
Mallbris, Lotus (Indianapolis, IN USA) ;
Augustin, Matthias (Hamburg, Germany) ;
Universitat Autònoma de Barcelona
2018 - 10.1007/s40257-018-0353-x
American Journal of Clinical Dermatology, Vol. 19 (march 2018) , p. 457
|
|
|
4.
|
|
8 p, 420.3 KB |
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders : A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
/
Blauvelt, Andrew (SW Locust St., Suite G, Portland, USA) ;
Papp, Kim A. (Waterloo, Canada) ;
Griffiths, Christopher E. M. (Manchester, UK) ;
Puig, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Weisman, Jamie (Medical Dermatology Specialists, Inc., Atlanta, GA USA) ;
Dutronc, Yves (Indianapolis, IN USA) ;
Kerr, Lisa Farmer (Indianapolis, IN USA) ;
Ilo, Dapo (Indianapolis, IN USA) ;
Mallbris, Lotus (Indianapolis, IN USA) ;
Augustin, Matthias (Hamburg, Germany) ;
Universitat Autònoma de Barcelona
Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. [...]
2017 - 10.1007/s40257-016-0246-9
American Journal of Clinical Dermatology, Vol. 18 (january 2017) , p. 273-280
|
|
|
5.
|
|
1 p, 338.7 KB |
Erratum to : Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
/
Adsit, Sandra (TCR Medical Corporation) ;
Zaldivar, Enrique Rivas (Dermos, Guatemala City, Guatemala) ;
Sofen, Howard (Los Angeles, CA USA) ;
Dei-Cas, Ignacio (Halitus, Buenos Aires, Argentina) ;
Maldonado-García, César (Centro Dermatológico "Dr. Ladislao de la Pascua", Mexico City, Mexico) ;
Peñaranda, Elkin O. (Riesgo de Fractura S.A., Bogota, Colombia) ;
Puig, Luís (Institut d'Investigació Biomèdica Sant Pau) ;
Meng, Xiangyi (East Hanover, NJ USA) ;
Fox, Todd (Basel, Switzerland) ;
Guana, Adriana (East Hanover, NJ USA) ;
Universitat Autònoma de Barcelona
Introduction: There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. [...]
2017 - 10.1007/s12325-017-0563-2
Advances in Therapy, Vol. 34 (june 2017) , p. 1772
|
|
|
6.
|
|
22 p, 1.1 MB |
Type 1 diabetes prevention in NOD mice by targeting DPPIV/CD26 is associated with changes in CD8+T effector memory subset
/
Alonso Pedrol, Núria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Julián, María Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Carrascal, Jorge (Institut Germans Trias i Pujol) ;
Colobrán Oriol, Roger (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Pujol Autonell, Irma (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rodriguez Fernandez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Teniente Serra, Aina (Institut Germans Trias i Pujol) ;
Fernández Sanmartin, Marco Antonio (Institut Germans Trias i Pujol) ;
Miñarro Alonso, Antoni (Universitat de Barcelona. Departament d'Estadística) ;
Ruiz de Villa, María del Carmen (Universitat de Barcelona. Departament d'Estadística) ;
Vives Pi, Marta (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Puig Domingo, Manuel Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
CD26 is a T cell activation marker consisting in a type II transmembrane glycoprotein with dipeptidyl peptidase IV (DPPIV) activity in its extracellular domain. It has been described that DPPIV inhibition delays the onset of type 1 diabetes and reverses the disease in non-obese diabetic (NOD) mice. [...]
2015 - 10.1371/journal.pone.0142186
PloS one, Vol. 10, Issue 11 (Novembre 2015) , p. e0142186
|
|
|
7.
|
|
19 p, 1.2 MB |
Use of autoantigen-loaded phosphatidylserine-liposomes to arrest autoimmunity in type 1 diabetes
/
Pujol Autonell, Irma (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Serracant Prat, Arnau (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cano-Sarabia, Mary (Institut Català de Nanociència i Nanotecnologia) ;
Ampudia, Rosa Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rodriguez Fernandez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sànchez, Àlex (Sànchez Pla) (Universitat de Barcelona. Departament d'Estadística) ;
Izquierdo Castro, Cristina (Universitat de Barcelona. Departament de Fisiologia i Immunologia) ;
Stratmann, Thomas (Universitat de Barcelona. Departament de Fisiologia i Immunologia) ;
Puig Domingo, Manuel Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Maspoch Comamala, Daniel (Institut Català de Nanociència i Nanotecnologia) ;
Verdaguer, Joan (Universitat de Lleida. Departament de Medicina Experimental) ;
Vives Pi, Marta (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Universitat Autònoma de Barcelona
INTRODUCTION: The development of new therapies to induce self-tolerance has been an important medical health challenge in type 1 diabetes. An ideal immunotherapy should inhibit the autoimmune attack, avoid systemic side effects and allow β-cell regeneration. [...]
2015 - 10.1371/journal.pone.0127057
PloS one, Vol. 19, Issue 6 (June 2015) , p. e0127057
|
|
|
8.
|
|
18 p, 388.9 KB |
Actuaciones de alumnos instruidos en la resolución algebraica de problemas en la hoja de cálculo y su relación con la competencia en el método cartesiano
/
Arnau, David (Universitat de València. Departamento de Didáctica de la Matemática) ;
Puig, Luis (Universitat de València. Departamento de Didáctica de la Matemática)
Presentamos resultados de una investigación en la que, entre otros objetivos, se pretendía determinar cómo influía la enseñanza de la resolución algebraica de problemas en la hoja de cálculo en la competencia en el método cartesiano. [...]
We present results of an investigation in which, among other objectives, we sought to determine how the teaching of algebraic problem solving in a spreadsheet environment influenced the competence in the Cartesian method. [...]
2013 - 10.5565/rev/ec/v31n3.967
Enseñanza de las ciencias, Vol. 31, Núm. 3 (2013) , p. 49-66
|
|
|
9.
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
